NGEN

NervGen Pharma Corp

Apr 02 • 04:00PM ET

4.26

-0.10 -2.29 %

Healthcare • Biotechnology • Canada • NASD

Apr 01, 8:30 PMFDA End-of-Phase 2 meeting completion propels shares 15.65% higher.

Index	-	P/E	-	EPS (ttm)	-0.42	Insider Own	21.50%	Shs Outstand	79.65M	Perf Week	16.39%
Market Cap	339.05M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	62.48M	Perf Month	-0.23%
Enterprise Value	322.95M	PEG	-	EPS next Q	-0.06	Inst Own	0.01%	Short Float	2.16%	Perf Quarter	-23.93%
Income	-31.64M	P/S	-	EPS this Y	36.73%	Inst Trans	-2.88%	Short Ratio	9.35	Perf Half Y	68.78%
Sales	0.00M	P/B	133.75	EPS next Y	12.78%	ROA	-207.62%	Short Interest	1.35M	Perf YTD	-23.93%
Book/sh	0.03	P/C	21.05	EPS next 5Y	-	ROE	-1462.20%	52W High	6.30 -32.38%	Perf Year	87.67%
Cash/sh	0.20	P/FCF	-	EPS past 3/5Y	-13.03% -10.94%	ROIC	-1247.48%	52W Low	1.50 184.00%	Perf 3Y	245.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.69% 6.51%	Perf 5Y	220.30%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-67.10%	Oper. Margin	-	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.95	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.16	EPS Q/Q	-186.86%	SMA20	8.38%	Beta	1.01	Target Price	6.49
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.54%	Rel Volume	4.24	Prev Close	4.36
Employees	8	LT Debt/Eq	0.00	Earnings	Mar 31 BMO	SMA200	24.52%	Avg Volume	144.40K	Price	4.26
IPO	Apr 03, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-163.00% -	Trades		Volume	611,809	Change	-2.29%

Mar-31-26 07:45AM	NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-12-26 04:15PM	NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange (GlobeNewswire) -6.98%
Mar-04-26 07:30AM	NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs (GlobeNewswire) +8.10%
Feb-18-26 07:30AM	NervGen Pharma to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-12-26 04:15PM	NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams (GlobeNewswire)
07:00AM	Loading…
Feb-11-26 07:00AM	NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium (GlobeNewswire)
Feb-09-26 07:00AM	NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury (GlobeNewswire)
Jan-20-26 07:00AM	NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing (GlobeNewswire) -6.93%
Jan-08-26 06:30AM	NervGen Pharma Begins Trading on Nasdaq Today (GlobeNewswire)

NervGen Pharma Corp. operates as a clinical stage biotech company. It provides development of treatment that enables the nervous system to repair itself following damage, whether due to injury or disease. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGEN

NervGen Pharma Corp

Upgrade your Finviz experience